Efficacy and Safety of FLOSEAL for Hemostasis in Total Knee Arthroplasty
Primary Purpose
Knee Replacement Surgery, Osteoarthritis
Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Standard of Care
FLOSEAL Hemostatic Matrix + Standard of care
Sponsored by

About this trial
This is an interventional treatment trial for Knee Replacement Surgery
Eligibility Criteria
Inclusion Criteria:
- Participant is 18 to 80 years of age inclusive at the time of screening
- Participant is planned for primary unilateral total knee arthroplasty
- Participant has signed the informed consent form
- Participant is in stable health (i.e., able to undergo surgery and participate in a follow-up program based on physical examination and medical history)
- Participant has a preoperative Hgb level > 10 g/dL
- If female of childbearing potential, the participant presents with a negative urine pregnancy test and agrees to employ adequate birth control measures for the duration of the study
- Participant is willing and able to comply with the requirements of the protocol
Exclusion Criteria:
- Participant has had a previous total or partial knee arthroplasty or any surgery on the knee within the previous 6 months
- Participant has osteonecrosis or arthrotomy within the last year
- Participant has prior or current hardware in target knee
Participant has had injections in the knee:
- Steroids within the 3 months prior to scheduled surgery,
- Synvisc, Hyalin, etc. within the 6 months prior to scheduled surgery
- Participant has had general surgery within 3 months
- Participant has rheumatoid arthritis or any other inflammatory or traumatic bone injuries to the knee within the 12 months prior to scheduled surgery
- Participant has allergies to products of bovine origin
- Participant has a history of bleeding, platelet, or bone marrow disorders
- Participant has donated more than 1 unit of blood donation in the 3 weeks prior to surgery
- Participant has a history of a coagulation disorder
- Participant is currently taking dipyridamole/ASA (Aggrenox) and/or enoxaparin (Lovenox)
- Participant has been treated with aspirin or Warfarin (Coumadin) or clopidogrel (Plavix) within 7 days prior to surgery
- Participant is not permitted to remain without his/her anti-coagulant regimen (e.g. Plavix) for 48 hours postoperatively
- Participant has taken nonsteroidal anti-inflammatory agents or herbal supplements within 7 days of surgery
- Participant has a history of substance abuse (alcohol, drugs) or is an active smoker
- Participant has liver cirrhosis
- Participant has erythropoietin agonist/stimulating agent within 90 days prior to surgery
- Participant has an active infection or previous history of infection in the affected joint within the previous 6 months
- Participant has participated in another clinical study involving an investigational product (IP) or device within 30 days prior to study enrollment or is scheduled to participate in another clinical study involving an IP or device during the course of this study
Sites / Locations
- Cedars-Sinai Orthopedic Center
- Stanford Orthopedics
- Colorado Orthopedic Consultants, PC
- George Washington University Medical Faculty Associates
- Florida Research Associates, LLC
- Shrock Orthopedic Research, LLC
- Phoenix Clinical Research, LLC
- Joint Replacement Surgeons of Indiana Foundations
- Rothman Institute
- The Rothman Institute, Philadelphia
- Temple University
- Hill Country Clinical Research, Inc.
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Experimental
Arm Label
Standard of Care (SoC)
FLOSEAL + Standard of Care (SoC)
Arm Description
SoC: conventional hemostatic techniques such as cautery and manual compression
FLOSEAL: consists of bovine-derived gelatin granules and a human plasma-derived thrombin component. SoC: conventional hemostatic techniques such as cautery and manual compression
Outcomes
Primary Outcome Measures
Change in Hemoglobin (Hgb) Level at Day 2 Post-operatively
Proportion of Participants Who Have Adverse Events Related to Investigational Product (IP)
Proportion of Participants who have serious injuries (SIs) related to IP
Proportion of Participants who have non-serious adverse events (non-SAEs) related to IP
Secondary Outcome Measures
Change in Hemoglobin (Hgb) Levels at Day 1 Post-operatively
Change in Hemoglobin (Hgb) Levels at Day 3 Post-operatively
Participants who required a transfusion prior to the outcome assessments were excluded from the efficacy analyses of Hgb levels.
Change From Baseline in Hematocrit (Hct) at Postoperative Day 1
Participants who required a transfusion prior to the outcome assessments were excluded from the efficacy analyses of Hct levels.
Change From Baseline in Hematocrit (Hct) at Postoperative Day 2
Change From Baseline in Hematocrit (Hct) at Postoperative Day 3
Total Tourniquet Time
Measured from the time point of the tourniquet inflation to deflation using the same watch/clock
Amount of FLOSEAL Applied
Duration of Surgery
Transfusion Requirements - Packed Red Blood Cells
Total Drain Output at Day 1 Post-operatively
Pain Management - Number of Days When Pain Medication Was Used
Each participant kept a knee pain management diary. The diary was used to document the pain medication taken on a daily basis.
While the participants were hospitalized, either they filled out the diary, or study team members collected the pain diary data and filled out the diary.
Visual Analogue Scale (VAS) Pain Scores
Participant rated assessment of the level of pain they are experiencing with their operated knee. The VAS Pain Scale rates pain on a scale from 0 (no pain) to 10 (worst possible pain). For the pain scale, a higher score indicates worse pain.
Change From Baseline in Visual Analogue Scale (VAS) Pain Scores at Postoperative Day 3
Participant rated assessment of the level of pain they are experiencing with their operated knee. The VAS Pain Scale rates pain on a scale from 0 (no pain) to 10 (worst possible pain). For the pain scale, a higher score indicates worse pain.
Change From Baseline in Visual Analogue Scale (VAS) Pain Scores at Postoperative Week 1
Participant rated assessment of the level of pain they are experiencing with their operated knee. The VAS Pain Scale rates pain on a scale from 0 (no pain) to 10 (worst possible pain). For the pain scale, a higher score indicates worse pain.
Change From Baseline in Visual Analogue Scale (VAS) Pain Scores at Postoperative Week 2
Participant rated assessment of the level of pain they are experiencing with their operated knee. The VAS Pain Scale rates pain on a scale from 0 (no pain) to 10 (worst possible pain). For the pain scale, a higher score indicates worse pain.
Change From Baseline in Visual Analogue Scale (VAS) Pain Scores at Postoperative Week 6
Participant rated assessment of the level of pain they are experiencing with their operated knee. The VAS Pain Scale rates pain on a scale from 0 (no pain) to 10 (worst possible pain). For the pain scale, a higher score indicates worse pain.
Western Ontario and McMaster Universities (WOMAC) Function Index Scores
A well-validated scale to reflect problems in people with lower limb issues.
Pain scale (5 items): 0 (none) to 10 (extreme pain) is used to grade each item, higher scores indicate greater pain. The overall pain scale = 0 (no pain) to 50 (extreme pain)
Stiffness scale (2 items): 0 (none) to 10 (extreme stiffness) is used to grade each item, higher scores indicate greater stiffness. The overall stiffness scale = 0 (no stiffness) to 20 (extreme stiffness)
Physical Activity Difficulty (PAD) scale (17 items): 0 (none) to 10 (extreme PAD) is used to grade each item, with higher scores indicating greater PAD. The overall PAD scale = 0 (no PAD) to 170 (extreme PAD)
Averages calculated by taking sum of all individual item scores listed above and dividing by total number of items, range = 0 (no issues) to 10 (extreme issues).
Total Scores calculated by taking sum of all individual item scores listed above, range = 0 (no issues) to 240 (extreme issues)
Postoperative (Postop)
Change From Baseline at Postoperative Day 3, Week 1, Week 2, and Week 6 in Western Ontario and McMaster Universities (WOMAC) Scores
A well-validated scale to reflect problems in people with lower limb issues.
Pain scale (5 items): 0 (none) to 10 (extreme pain) is used to grade each item, higher scores indicate greater pain. The overall pain scale = 0 (no pain) to 50 (extreme pain)
Stiffness scale (2 items): 0 (none) to 10 (extreme stiffness) is used to grade each item, higher scores indicate greater stiffness. The overall stiffness scale = 0 (no stiffness) to 20 (extreme stiffness)
Physical Activity Difficulty (PAD) scale (17 items): 0 (none) to 10 (extreme PAD) is used to grade each item, with higher scores indicating greater PAD. The overall PAD scale = 0 (no PAD) to 170 (extreme PAD) Averages calculated by taking sum of all individual item scores listed above and dividing by total number of items, range = 0 (no issues) to 10 (extreme issues).
Total Scores calculated by taking sum of all individual item scores listed above, range = 0 (no issues) to 240 (extreme issues).
Postoperative (Postop)
Quality of Life (Utilizing the Short Form 36 Health Survey [SF-36]) Measured Preoperatively (Baseline), and Postoperatively at Week 1, 2, and 6
Physical Functioning (PF); Role Limitation Due to Physical Health (RP); Bodily Pain (BP); General Health (GH); Vitality (VT); Social Functioning (SF); Role Limitation Due to Emotional Problems (RE); Mental Health (MH), Physical Component Score (PCS); Mental Component Score (MCS). Scores range 0-100, higher scores represent better health. There is no total overall score; scoring is done for subscores and summary scores. Scores were included where data was available.
Change From Baseline in SF-36 Scores at Postoperative Weeks 1, 2, and 6
Physical Functioning (PF); Role Limitation Due to Physical Health (RP); Bodily Pain (BP); General Health (GH); Vitality (VT); Social Functioning (SF); Role Limitation Due to Emotional Problems (RE); Mental Health (MH), Physical Component Score (PCS); Mental Component Score (MCS). Scores range 0-100, higher scores represent better health. There is no total overall score; scoring is done for subscores and summary scores. Scores were included where data was available.
Change in SF-36 Scores From Baseline = (Postoperative Week 1,2, or 6 Scores) - (Baseline Scores).
Length of Hospital Stay
Proportion of Participants With Transfusion Requirements
Proportion of Participants With Wound Complications (ie, Hematoma, Cellulitis, Dehiscence, Superficial or Deep Infection, and Persistent Drainage)
Proportion of Participants With Any Adverse Events or Serious Injuries During or After Surgery
Rehabilitation Parameter by Study Day- Number of Participants Who Saw Their Physical Therapist
The number of participants responding affirmative in their rehabilitation diaries for each day
Rehabilitation Parameter by Study Day- Number of Participants Who Were Able to Walk Without Assistance
The number of participants responding affirmative in their rehabilitation diaries for each day
Rehabilitation Parameter by Study Day- Number of Participants Who Were Using a Walker
The number of participants responding affirmative in their rehabilitation diaries for each day
Rehabilitation Parameter by Study Day- Number of Participants Who Were Using a Walking Cane
The number of participants responding affirmative in their rehabilitation diaries for each day
Rehabilitation Parameter by Study Day- Number of Participants Who Were Using a Wheelchair
The number of participants responding affirmative in their rehabilitation diaries for each day
Rehabilitation Parameter by Study Day- Number of Participants Who Were Using a Another Walking Device (Other Than a: Walker, Walking Cane, or Wheelchair)
The number of participants responding affirmative in their rehabilitation diaries for each day
Rehabilitation Parameter by Study Day- Number of Participants Who Cannot Get Out of Bed
The number of participants responding affirmative in their rehabilitation diaries for each day
Rehabilitation Parameter by Study Day- Number of Participants Who Had Someone Helping Them to Walk
The number of participants responding affirmative in their rehabilitation diaries for each day
Full Information
NCT ID
NCT01410240
First Posted
August 1, 2011
Last Updated
May 15, 2014
Sponsor
Baxter Healthcare Corporation
1. Study Identification
Unique Protocol Identification Number
NCT01410240
Brief Title
Efficacy and Safety of FLOSEAL for Hemostasis in Total Knee Arthroplasty
Official Title
A Prospective, Randomized, Controlled, Single-Blinded, Multicenter Study to Evaluate the Efficacy and Safety of FLOSEAL for Hemostasis in Primary Unilateral Total Knee Arthroplasty (TKA)
Study Type
Interventional
2. Study Status
Record Verification Date
May 2014
Overall Recruitment Status
Completed
Study Start Date
September 2011 (undefined)
Primary Completion Date
January 2013 (Actual)
Study Completion Date
January 2013 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Baxter Healthcare Corporation
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to compare the efficacy and safety of FLOSEAL to standard of care for hemostasis in subjects undergoing total knee arthroplasty.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Knee Replacement Surgery, Osteoarthritis
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
137 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Standard of Care (SoC)
Arm Type
Active Comparator
Arm Description
SoC: conventional hemostatic techniques such as cautery and manual compression
Arm Title
FLOSEAL + Standard of Care (SoC)
Arm Type
Experimental
Arm Description
FLOSEAL: consists of bovine-derived gelatin granules and a human plasma-derived thrombin component.
SoC: conventional hemostatic techniques such as cautery and manual compression
Intervention Type
Procedure
Intervention Name(s)
Standard of Care
Intervention Description
Conventional hemostatic techniques, such as cautery and manual compression, will be used.
Intervention Type
Drug
Intervention Name(s)
FLOSEAL Hemostatic Matrix + Standard of care
Other Intervention Name(s)
FLOSEAL
Intervention Description
FLOSEAL will be applied topically to areas of the knee where bleeding is observed (e.g. cut bone surfaces, subcutaneous tissue, posterior joint capsule, synovial tissue, medial and lateral gutters, branches of the genicular vessels, and suprapatellar pouch) and will occur intraoperatively. Sufficient amounts of FLOSEAL will be applied quickly using the provided applicators, followed by immediate approximation with a damp gauze, lap pad or sponge for approximately 2 minutes.
+ Standard of care: conventional hemostatic techniques, such as cautery and manual compression, will be used
Primary Outcome Measure Information:
Title
Change in Hemoglobin (Hgb) Level at Day 2 Post-operatively
Time Frame
Pre-operative and 2 days post-operatively
Title
Proportion of Participants Who Have Adverse Events Related to Investigational Product (IP)
Description
Proportion of Participants who have serious injuries (SIs) related to IP
Proportion of Participants who have non-serious adverse events (non-SAEs) related to IP
Time Frame
Throughout the study period, 1 year and 4 months
Secondary Outcome Measure Information:
Title
Change in Hemoglobin (Hgb) Levels at Day 1 Post-operatively
Time Frame
Pre-operative and day 1 post-operatively
Title
Change in Hemoglobin (Hgb) Levels at Day 3 Post-operatively
Description
Participants who required a transfusion prior to the outcome assessments were excluded from the efficacy analyses of Hgb levels.
Time Frame
Pre-operative and day 3 post-operatively
Title
Change From Baseline in Hematocrit (Hct) at Postoperative Day 1
Description
Participants who required a transfusion prior to the outcome assessments were excluded from the efficacy analyses of Hct levels.
Time Frame
Pre-operative and day 1 post-operatively
Title
Change From Baseline in Hematocrit (Hct) at Postoperative Day 2
Time Frame
Pre-operative and day 2 post-operatively
Title
Change From Baseline in Hematocrit (Hct) at Postoperative Day 3
Time Frame
Pre-operative and day 3 post-operatively
Title
Total Tourniquet Time
Description
Measured from the time point of the tourniquet inflation to deflation using the same watch/clock
Time Frame
Intra-operatively (on day of surgery = Day 0)
Title
Amount of FLOSEAL Applied
Time Frame
Intra-operatively (Day 0)
Title
Duration of Surgery
Time Frame
Time from first incision to complete wound closure (Day 0)
Title
Transfusion Requirements - Packed Red Blood Cells
Time Frame
Intra-operatively (Day 0) thru Postoperative Day 3
Title
Total Drain Output at Day 1 Post-operatively
Time Frame
1 day post-operatively
Title
Pain Management - Number of Days When Pain Medication Was Used
Description
Each participant kept a knee pain management diary. The diary was used to document the pain medication taken on a daily basis.
While the participants were hospitalized, either they filled out the diary, or study team members collected the pain diary data and filled out the diary.
Time Frame
Pre-operatively (Day -1 to Day 0); and post-operatively daily thru week 6
Title
Visual Analogue Scale (VAS) Pain Scores
Description
Participant rated assessment of the level of pain they are experiencing with their operated knee. The VAS Pain Scale rates pain on a scale from 0 (no pain) to 10 (worst possible pain). For the pain scale, a higher score indicates worse pain.
Time Frame
Pre-operatively (Day -1 to Day 0) and post-operatively at Day 3, Week 1, 2 and 6
Title
Change From Baseline in Visual Analogue Scale (VAS) Pain Scores at Postoperative Day 3
Description
Participant rated assessment of the level of pain they are experiencing with their operated knee. The VAS Pain Scale rates pain on a scale from 0 (no pain) to 10 (worst possible pain). For the pain scale, a higher score indicates worse pain.
Time Frame
Pre-operatively (Day -1 to Day 0) and post-operatively at Day 3
Title
Change From Baseline in Visual Analogue Scale (VAS) Pain Scores at Postoperative Week 1
Description
Participant rated assessment of the level of pain they are experiencing with their operated knee. The VAS Pain Scale rates pain on a scale from 0 (no pain) to 10 (worst possible pain). For the pain scale, a higher score indicates worse pain.
Time Frame
Pre-operatively (Day -1 to Day 0) and post-operatively at Week 1
Title
Change From Baseline in Visual Analogue Scale (VAS) Pain Scores at Postoperative Week 2
Description
Participant rated assessment of the level of pain they are experiencing with their operated knee. The VAS Pain Scale rates pain on a scale from 0 (no pain) to 10 (worst possible pain). For the pain scale, a higher score indicates worse pain.
Time Frame
Pre-operatively (Day -1 to Day 0) and post-operatively at Week 2
Title
Change From Baseline in Visual Analogue Scale (VAS) Pain Scores at Postoperative Week 6
Description
Participant rated assessment of the level of pain they are experiencing with their operated knee. The VAS Pain Scale rates pain on a scale from 0 (no pain) to 10 (worst possible pain). For the pain scale, a higher score indicates worse pain.
Time Frame
Pre-operatively (Day -1 to Day 0) and post-operatively at Week 6
Title
Western Ontario and McMaster Universities (WOMAC) Function Index Scores
Description
A well-validated scale to reflect problems in people with lower limb issues.
Pain scale (5 items): 0 (none) to 10 (extreme pain) is used to grade each item, higher scores indicate greater pain. The overall pain scale = 0 (no pain) to 50 (extreme pain)
Stiffness scale (2 items): 0 (none) to 10 (extreme stiffness) is used to grade each item, higher scores indicate greater stiffness. The overall stiffness scale = 0 (no stiffness) to 20 (extreme stiffness)
Physical Activity Difficulty (PAD) scale (17 items): 0 (none) to 10 (extreme PAD) is used to grade each item, with higher scores indicating greater PAD. The overall PAD scale = 0 (no PAD) to 170 (extreme PAD)
Averages calculated by taking sum of all individual item scores listed above and dividing by total number of items, range = 0 (no issues) to 10 (extreme issues).
Total Scores calculated by taking sum of all individual item scores listed above, range = 0 (no issues) to 240 (extreme issues)
Postoperative (Postop)
Time Frame
Pre-operatively (Day -1 to Day 0), and post-operatively at Day 3 and Week 1, 2 and 6
Title
Change From Baseline at Postoperative Day 3, Week 1, Week 2, and Week 6 in Western Ontario and McMaster Universities (WOMAC) Scores
Description
A well-validated scale to reflect problems in people with lower limb issues.
Pain scale (5 items): 0 (none) to 10 (extreme pain) is used to grade each item, higher scores indicate greater pain. The overall pain scale = 0 (no pain) to 50 (extreme pain)
Stiffness scale (2 items): 0 (none) to 10 (extreme stiffness) is used to grade each item, higher scores indicate greater stiffness. The overall stiffness scale = 0 (no stiffness) to 20 (extreme stiffness)
Physical Activity Difficulty (PAD) scale (17 items): 0 (none) to 10 (extreme PAD) is used to grade each item, with higher scores indicating greater PAD. The overall PAD scale = 0 (no PAD) to 170 (extreme PAD) Averages calculated by taking sum of all individual item scores listed above and dividing by total number of items, range = 0 (no issues) to 10 (extreme issues).
Total Scores calculated by taking sum of all individual item scores listed above, range = 0 (no issues) to 240 (extreme issues).
Postoperative (Postop)
Time Frame
Pre-operatively (Day -1 to Day 0), and post-operatively at Day 3 and Week 1, 2 and 6
Title
Quality of Life (Utilizing the Short Form 36 Health Survey [SF-36]) Measured Preoperatively (Baseline), and Postoperatively at Week 1, 2, and 6
Description
Physical Functioning (PF); Role Limitation Due to Physical Health (RP); Bodily Pain (BP); General Health (GH); Vitality (VT); Social Functioning (SF); Role Limitation Due to Emotional Problems (RE); Mental Health (MH), Physical Component Score (PCS); Mental Component Score (MCS). Scores range 0-100, higher scores represent better health. There is no total overall score; scoring is done for subscores and summary scores. Scores were included where data was available.
Time Frame
Preoperative, and Postoperative Weeks 1, 2, and 6
Title
Change From Baseline in SF-36 Scores at Postoperative Weeks 1, 2, and 6
Description
Physical Functioning (PF); Role Limitation Due to Physical Health (RP); Bodily Pain (BP); General Health (GH); Vitality (VT); Social Functioning (SF); Role Limitation Due to Emotional Problems (RE); Mental Health (MH), Physical Component Score (PCS); Mental Component Score (MCS). Scores range 0-100, higher scores represent better health. There is no total overall score; scoring is done for subscores and summary scores. Scores were included where data was available.
Change in SF-36 Scores From Baseline = (Postoperative Week 1,2, or 6 Scores) - (Baseline Scores).
Time Frame
Baseline and Postoperative Weeks 1, 2, and 6
Title
Length of Hospital Stay
Time Frame
From the day of hospitalization to the day of discharge
Title
Proportion of Participants With Transfusion Requirements
Time Frame
Intra-operative
Title
Proportion of Participants With Wound Complications (ie, Hematoma, Cellulitis, Dehiscence, Superficial or Deep Infection, and Persistent Drainage)
Time Frame
Day 0; Post-operative Days 1, 3 and Weeks 1, 2, 6
Title
Proportion of Participants With Any Adverse Events or Serious Injuries During or After Surgery
Time Frame
Day 0; Post-operative Days 1, 3 and Weeks 1, 2, 6
Title
Rehabilitation Parameter by Study Day- Number of Participants Who Saw Their Physical Therapist
Description
The number of participants responding affirmative in their rehabilitation diaries for each day
Time Frame
60 days
Title
Rehabilitation Parameter by Study Day- Number of Participants Who Were Able to Walk Without Assistance
Description
The number of participants responding affirmative in their rehabilitation diaries for each day
Time Frame
60 days
Title
Rehabilitation Parameter by Study Day- Number of Participants Who Were Using a Walker
Description
The number of participants responding affirmative in their rehabilitation diaries for each day
Time Frame
60 days
Title
Rehabilitation Parameter by Study Day- Number of Participants Who Were Using a Walking Cane
Description
The number of participants responding affirmative in their rehabilitation diaries for each day
Time Frame
60 days
Title
Rehabilitation Parameter by Study Day- Number of Participants Who Were Using a Wheelchair
Description
The number of participants responding affirmative in their rehabilitation diaries for each day
Time Frame
60 days
Title
Rehabilitation Parameter by Study Day- Number of Participants Who Were Using a Another Walking Device (Other Than a: Walker, Walking Cane, or Wheelchair)
Description
The number of participants responding affirmative in their rehabilitation diaries for each day
Time Frame
60 days
Title
Rehabilitation Parameter by Study Day- Number of Participants Who Cannot Get Out of Bed
Description
The number of participants responding affirmative in their rehabilitation diaries for each day
Time Frame
60 days
Title
Rehabilitation Parameter by Study Day- Number of Participants Who Had Someone Helping Them to Walk
Description
The number of participants responding affirmative in their rehabilitation diaries for each day
Time Frame
60 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Participant is 18 to 80 years of age inclusive at the time of screening
Participant is planned for primary unilateral total knee arthroplasty
Participant has signed the informed consent form
Participant is in stable health (i.e., able to undergo surgery and participate in a follow-up program based on physical examination and medical history)
Participant has a preoperative Hgb level > 10 g/dL
If female of childbearing potential, the participant presents with a negative urine pregnancy test and agrees to employ adequate birth control measures for the duration of the study
Participant is willing and able to comply with the requirements of the protocol
Exclusion Criteria:
Participant has had a previous total or partial knee arthroplasty or any surgery on the knee within the previous 6 months
Participant has osteonecrosis or arthrotomy within the last year
Participant has prior or current hardware in target knee
Participant has had injections in the knee:
Steroids within the 3 months prior to scheduled surgery,
Synvisc, Hyalin, etc. within the 6 months prior to scheduled surgery
Participant has had general surgery within 3 months
Participant has rheumatoid arthritis or any other inflammatory or traumatic bone injuries to the knee within the 12 months prior to scheduled surgery
Participant has allergies to products of bovine origin
Participant has a history of bleeding, platelet, or bone marrow disorders
Participant has donated more than 1 unit of blood donation in the 3 weeks prior to surgery
Participant has a history of a coagulation disorder
Participant is currently taking dipyridamole/ASA (Aggrenox) and/or enoxaparin (Lovenox)
Participant has been treated with aspirin or Warfarin (Coumadin) or clopidogrel (Plavix) within 7 days prior to surgery
Participant is not permitted to remain without his/her anti-coagulant regimen (e.g. Plavix) for 48 hours postoperatively
Participant has taken nonsteroidal anti-inflammatory agents or herbal supplements within 7 days of surgery
Participant has a history of substance abuse (alcohol, drugs) or is an active smoker
Participant has liver cirrhosis
Participant has erythropoietin agonist/stimulating agent within 90 days prior to surgery
Participant has an active infection or previous history of infection in the affected joint within the previous 6 months
Participant has participated in another clinical study involving an investigational product (IP) or device within 30 days prior to study enrollment or is scheduled to participate in another clinical study involving an IP or device during the course of this study
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ildiko Szabo, MD, MBA
Organizational Affiliation
Baxter Innovations GmbH
Official's Role
Study Director
Facility Information:
Facility Name
Cedars-Sinai Orthopedic Center
City
Los Angeles
State/Province
California
ZIP/Postal Code
90042
Country
United States
Facility Name
Stanford Orthopedics
City
Redwood City
State/Province
California
ZIP/Postal Code
94063
Country
United States
Facility Name
Colorado Orthopedic Consultants, PC
City
Englewood
State/Province
Colorado
ZIP/Postal Code
80110
Country
United States
Facility Name
George Washington University Medical Faculty Associates
City
Washington
State/Province
District of Columbia
ZIP/Postal Code
20037
Country
United States
Facility Name
Florida Research Associates, LLC
City
DeLand
State/Province
Florida
ZIP/Postal Code
32720
Country
United States
Facility Name
Shrock Orthopedic Research, LLC
City
Ft. Lauderdale
State/Province
Florida
ZIP/Postal Code
33316
Country
United States
Facility Name
Phoenix Clinical Research, LLC
City
Tamarac
State/Province
Florida
ZIP/Postal Code
33321
Country
United States
Facility Name
Joint Replacement Surgeons of Indiana Foundations
City
Mooresville
State/Province
Indiana
ZIP/Postal Code
46158
Country
United States
Facility Name
Rothman Institute
City
Egg Harbor Township
State/Province
New Jersey
ZIP/Postal Code
08234-5500
Country
United States
Facility Name
The Rothman Institute, Philadelphia
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19107
Country
United States
Facility Name
Temple University
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19140
Country
United States
Facility Name
Hill Country Clinical Research, Inc.
City
Austin,
State/Province
Texas
ZIP/Postal Code
78759
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Efficacy and Safety of FLOSEAL for Hemostasis in Total Knee Arthroplasty
We'll reach out to this number within 24 hrs